Last updated 2026-07-20
- Raised $40M Series B led by Leaps by Bayer, Dec 2020
- Raised $7.7M Series A led by Marc Benioff, Jun 2017
- Raised Series C led by Sanara Capital, May 2025
Total raised
$47.7M
Last: Undisclosed Round 2025-06
Stage
Series A
Founded
2016
Headcount
51
HQ
Rehovot, Israel
Sector
Agriculture & Food Technologies
About
Ukko is a biotechnology company dedicated to designing safe immunotherapies to rapidly treat allergies and other immune-mediated conditions. The company utilizes an advanced computational protein design platform, leveraging AI and protein micro-engineering, to create modified allergens that do not trigger immune reactions. This innovative approach aims to re-educate the immune system, fostering tolerance rather than allergic response, and offering a new modality for allergy treatment. Ukko's initial product pipeline includes celiac-safe gluten proteins, allergy-safe and therapeutic peanut proteins.
Funding history · 3 rounds · $47.7M total
2025-05
C Round
Undisclosed
★ Sanara Capital
2020-12
B Round
$40.0M
★ Leaps by BayerPeakBridgeMarc BenioffKhosla VenturesFall Line CapitalSkyviews LifeScienceInnovation EndeavorsContinental Grain Company
2017-06
A Round
$7.7M
★ Marc Benioff★ Izhar Armony★ Slow Ventures★ Khosla Ventures★ Innovation Endeavors
Headcount over time
From 13 (2019-02) to 54 (2025-12) · +41 (+315%) · 17 points · source: Finder history + radar grounding
Q&A
- What is Ukko's primary mission?
- Ukko's mission is to improve the lives of people with food allergies and sensitivities by using immunology, machine learning, and protein engineering to create safer proteins for food and therapeutics.
- How much funding has Ukko raised in total?
- Ukko has raised a total of $47.7 million USD.
- Which investors participated in Ukko's July 2017 funding round?
- In July 2017, Ukko received funding from investors including Marc Benioff.
- Who led Ukko's January 2021 funding round?
- Ukko's January 2021 funding round was led by Leaps by Bayer, with participation from Khosla Ventures.
- Where is Ukko's headquarters located?
- Ukko's headquarters is located in Rehovot, Center District, Israel.
- What types of proteins are in Ukko's initial product pipeline?
- Ukko's initial product pipeline includes celiac-safe gluten proteins and allergy-safe and therapeutic peanut proteins.
Team · 2
Anat Binur
Founder · Co-founder & CEO
Yanay Ofran
Founder · Co-founder & Chairman
Sectors & technology
Primary sector
Agriculture & Food Technologies
Sub-sectors
Agriculture & Food TechnologiesFood TechNovel Food & Ingredients
Technologies
Artificial IntelligenceBiologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsAgriculture & FoodProcessed FoodsIngredients
Business model
B2B
Highlights
Verified
Tags
biotechnologyfoodtechfood-ingredientsmolecular-biologyconsumersbig-datapharmaceuticalstherapeuticsimmunologyallergyproteinsartificial-intelligence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | ukko.us/ |
|---|---|
| linkedin.com/company/18374287 | |
| Wikidata | wikidata.org/wiki/Q136913137 |
Identifiers & details
| Founded | 2016-5 |
|---|---|
| Employees (exact) | 51 |
| Offices | Palo Alto |
| Wikidata QID | Q136913137 |
Radar intelligence
Patents
| EPO | 21 |
|---|
Publications (Crossref)
| Works | 1 |
|---|
Web history (Wayback)
| Domain | ukko.us |
|---|
Wikidata
| QID | Q136913137 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515685550 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2017-07-09 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 2 — violation (1), annual_report (1) |
| Registered address | המדע 12 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-28 | עדכון הפרה |
| 2026-06-28 | דו~ח שנתי |